keyword
MENU ▼
Read by QxMD icon Read
search

Chronic hepatitis c

keyword
https://www.readbyqxmd.com/read/29228501/hcv-clearance-by-direct-acting-antiviral-treatments-reverses-insulin-resistance-in-chronic-hepatitis-c-patients
#1
Luigi E Adinolfi, Riccardo Nevola, Barbara Guerrera, Giovanni D'Alterio, Aldo Marrone, Mauro Giordano, Luca Rinaldi
BACKGROUND AND AIM: Chronic hepatitis C (HCV), particularly genotype 1, is associated with insulin resistance (IR) and diabetes. We evaluated the impact of HCV clearance by all-oral direct-acting antiviral (DAAs) treatments on IR and glycemic control. METHODS: Included in this prospective case-control study were 133 consecutive HCV-genotype 1 patients with advance liver fibrosis (F3-F4) without type 2 diabetes. Sixty-eight treated with DAAs and 65 untreated. Liver fibrosis was assessed by transient elastography...
December 11, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29228430/mediation-of-inflammation-obesity-and-fatty-liver-disease-by-advanced-glycation-endoproducts
#2
D-D Xiong, M Zhang, N Li, J-F Gai, L Mao, M Li
OBJECTIVE: Fatty liver may induce various complications including chronic hepatitis or liver cirrhosis, and is frequently occurred in obesity individuals. Advanced glycosylation end products (AGEs) were known to play a critical role in multiple liver diseases. This study, therefore, aimed to study the effect of AGEs on obesity, related liver cirrhosis and inflammation, on an obesity fatty liver rat model. MATERIALS AND METHODS: A total of 60 Sprague Dawley (SD) rats were randomly divided into control, model and AGEs inhibitor groups (n=20 each)...
November 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/29228388/caspase-inhibition-reduces-hepatic-tissue-factor-driven-coagulation-in-vitro-and-in-vivo
#3
Anna K Kopec, Alfred P Spada, Patricia C Contreras, Nigel Mackman, James P Luyendyk
Tissue factor (TF) is the primary activator of the blood coagulation cascade. Liver parenchymal cells (i.e., hepatocytes) express TF in a molecular state that lacks procoagulant activity. Hepatocyte apoptosis is an important feature of acute and chronic liver diseases, and Fas-induced apoptosis increases hepatocyte TF procoagulant activity in vitro. We determined the impact of a pan-caspase inhibitor, IDN-7314, on hepatocyte TF activity in vitro and TF-mediated coagulation in vivo. Treatment of primary mouse hepatocytes with the Fas death receptor ligand (Jo2, 0...
December 7, 2017: Toxicological Sciences: An Official Journal of the Society of Toxicology
https://www.readbyqxmd.com/read/29227878/harm-reduction-based-and-peer-supported-hepatitis-c-treatment-for-people-who-inject-drugs-in-georgia
#4
Tamar Kikvidze, Niklas Luhmann, Elisabeth Avril, Maia Butsashvili, Konstantine Labartkava, Aurélie Etienne, Diane Le Pluart, Ina Inaridze, Ana Gamezardashvili, David Kharshiladze, Julie Bouscaillou
BACKGROUNDS: Georgia faces high HCV rates (5.4% of chronic cases in general population) with an epidemic concentrated among people who inject drugs (PWID). A National HCV Elimination Program (NHCEP), was launched in April 2015, aiming to eliminate HCV by 2020. To succeed, this program must develop tailored interventions to enroll PWID in treatment. INTERVENTION: We implemented a pilot intervention to facilitate access to and retention of PWID in the NHCEP, and to prevent reinfection after treatment...
December 8, 2017: International Journal on Drug Policy
https://www.readbyqxmd.com/read/29227418/development-and-validation-of-surveillance-based-algorithms-to-estimate-hepatitis-c-treatment-and-cure-in-new-york-city
#5
Miranda S Moore, Angelica Bocour, Lizeyka Jordan, Emily McGibbon, Jay K Varma, Ann Winters, Fabienne Laraque
CONTEXT: Treatment options for chronic hepatitis C virus (HCV) have improved in recent years. The burden of HCV in New York City (NYC) is high. Measuring treatment and cure among NYC residents with HCV infection will allow the NYC Department of Health and Mental Hygiene (DOHMH) to appropriately plan interventions, allocate resources, and identify disparities to combat the hepatitis C epidemic in NYC. OBJECTIVE: To validate algorithms designed to estimate treatment and cure of HCV using RNA test results reported through routine surveillance...
December 7, 2017: Journal of Public Health Management and Practice: JPHMP
https://www.readbyqxmd.com/read/29226638/reference-values-of-certain-serum-indicators-of-liver-fibrosis
#6
Blagovesta Pencheva, Rossen Mihajlov, Adelaida Ruseva, Rumyana Mitova, Kaloyan Petrov, Gergana Taneva, Jordan Genov
BACKGROUND: Liver fibrosis shows a continuously increasing trend worldwide, due to alcohol abuse, obesity, and, to a lesser extent, chronic hepatitis B and C. Biopsy is still considered the "gold standard" for diagnosis of liver fibrosis. However, it has a number of limitations, such as invasiveness, high cost, need for specialists to conduct and interpret biopsy results, risk of complications, inability to dynamically monitor the pathological process, low patient compliance, and uneven fibrosis distribution...
November 1, 2017: Clinical Laboratory
https://www.readbyqxmd.com/read/29226102/timing-of-hepatitis-c-virus-treatment-in-liver-transplant-candidates-in-the-era-of-direct-acting-antiviral-agents
#7
REVIEW
George Cholankeril, Mairin Joseph-Talreja, Brandon J Perumpail, Andy Liu, Eric R Yoo, Aijaz Ahmed, Aparna Goel
Chronic hepatitis C virus (HCV) infection remains the leading indication for liver transplantation (LT) in the United States. While most patients with chronic HCV infection remain asymptomatic, up to one-third develop progressive liver disease resulting in cirrhosis. LT is often the only curative treatment once significant hepatic decompensation develops. However, antiviral therapy for HCV infection has advanced markedly in the past 5 years with the discovery and approval of direct-acting antiviral agents. These new regimens are well tolerated, of short duration and highly effective, unlike the traditional treatment with pegylated-interferon and ribavirin...
December 28, 2017: Journal of Clinical and Translational Hepatology
https://www.readbyqxmd.com/read/29226101/risk-of-cardiovascular-disease-due-to-chronic-hepatitis-c-infection-a-review
#8
REVIEW
Ahmed Babiker, Jean Jeudy, Seth Kligerman, Miriam Khambaty, Anoop Shah, Shashwatee Bagchi
Hepatitis C (HCV) infection has an estimated global prevalence of 2.5%, causing chronic liver disease in 170 million people worldwide. Recent data has identified HCV infection as a risk factor for subclinical and clinical cardiovascular disease (CVD), but these data have been mixed and whether HCV is an independent risk factor for development of CVD remains controversial. In this review, we present the literature regarding the association of HCV with subclinical and clinical CVD and the possible underlying mechanisms leading to increased CVD among those infected with HCV...
December 28, 2017: Journal of Clinical and Translational Hepatology
https://www.readbyqxmd.com/read/29226099/efficacy-and-safety-of-direct-acting-antivirals-in-hepatitis-c-virus-infected-patients-taking-proton-pump-inhibitors
#9
Karn Wijarnpreecha, Supavit Chesdachai, Charat Thongprayoon, Veeravich Jaruvongvanich, Patompong Ungprasert, Wisit Cheungpasitporn
Background and Aims: Direct-acting antiviral (DAA) therapy is the cornerstone of the treatment of chronic hepatitis C virus (HCV) infection. Eradication of HCV, predicted by the attainment of a sustained virologic response (SVR) 12 weeks following DAA therapy, is the goal of this treatment. Interestingly, recent studies have reported the possible association between HCV-infected patients with DAA therapy concomitant use of proton pump inhibitors (PPIs) and lower odds of achieving SVR. This meta-analysis was conducted to summarize all available data and to estimate this potential association...
December 28, 2017: Journal of Clinical and Translational Hepatology
https://www.readbyqxmd.com/read/29225269/late-relapse-after-a-sustained-virologic-response-at-24-weeks-after-treatment-with-daclatasvir-and-asunaprevir-combination-therapy-for-chronic-hepatitis-c-virus-genotype-1b-infection-with-liver-cirrhosis
#10
Haruki Uojima, Shuko Murakami, Seigo Nakatani, Hisashi Hidaka, Atsuko Takeuchi, Yoshiaki Tanaka, Tomoyoshi Inoue, Keiko Yamane, Kousuke Kubota, Takahide Nakazawa, Akitaka Shibuya, Yasuhito Tanaka, Wasaburo Koizumi
There have been few studies on relapse after a sustained virological response in hepatitis C virus (HCV) patients treated with interferon-free regimens. Thus, the risk of late relapse in patients treated with interferon-free therapy remains unclear. A 67-year-old woman with HCV genotype 1b and liver cirrhosis received oral daclatasvir and asunaprevir. Combination therapy was stopped after 4 weeks because of an episode of encephalopathy. Nonetheless, an HCV polymerase chain reaction at 24 weeks posttreatment was negative...
December 8, 2017: Internal Medicine
https://www.readbyqxmd.com/read/29225215/cognitive-impairment-with-interferon-treatment-in-patients-with-chronic-hepatitis-c
#11
Hiroto Tanaka, Hideyuki Sasaki
Interferon (IFN) has various side effects, including psychiatric symptoms. Event-related potentials are used as an electrophysiologic index of cognitive disorders. Auditory event-related potentials (P300) are often used in conditions in which cognitive ability is affected. In this study, we evaluated the association between P300, used to assess cognitive impairment, and neuropsychological side effects of IFN treatment in patients with chronic hepatitis C. Subjects were 20 patients with chronic hepatitis C; 13 patients were treated with peg IFN-α2b and ribavirin (riba group), and 7 patients were treated with peg IFN-α2a (alone group)...
2017: Biomedical Research
https://www.readbyqxmd.com/read/29224736/a-natural-small-molecule-inhibitor-corilagin-blocks-hcv-replication-and-modulates-oxidative-stress-to-reduce-liver-damage
#12
B Uma Reddy, Ranajoy Mullick, Anuj Kumar, Geetika Sharma, Paromita Bag, Chaitrali Laha Roy, Govindarajan Sudha, Himani Tandon, Pratik Dave, Asutosh Shukla, Priyanka Srinivasan, Madhusudhan Nandhitha, Narayanaswamy Srinivasan, Saumitra Das
Hepatitis C virus (HCV) infection causes chronic liver disease, which often leads to hepatocellular carcinoma. Earlier, we have demonstrated anti-HCV property of the methanolic extract of Phyllanthus amarus, an age-old folk-medicine against viral hepatitis. Here, we report identification of a principal bioactive component 'corilagin', which showed significant inhibition of the HCV key enzymes, NS3 protease and NS5B RNA-dependent-RNA-polymerase. This pure compound could effectively inhibit viral replication in the infectious cell culture system, displayed strong antioxidant activity by blocking HCV induced generation of reactive oxygen species and suppressed up-regulation of NOX4 and TGF-β mRNA levels...
December 7, 2017: Antiviral Research
https://www.readbyqxmd.com/read/29221787/evaluation-of-alternative-serum-biomarkers-to-monitor-the-progression-of-chronic-hbv-and-hcv-infection
#13
S Tsiomita, U Georgopoulou, P P Doumba, J Koskinas, K Adamidis, C Papaloukas, G Thyphronitis
Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are among the most serious health conditions affecting about 600 million people worldwide leading to a number of severe liver diseases. Due to the lack of warning signs or mild symptoms during the early stage of the infection, a molecular signature associated with disease progression would be useful. Based on our recent paper where candidate biomarkers were determined through topological and modularity analysis of protein interaction networks (PINs), this study was focused on the evaluation of MIF, TNFRSF1A, FAS and TMSB4X as diagnostic biomarkers in chronic HBV and HCV infections...
December 6, 2017: Infection, Genetics and Evolution
https://www.readbyqxmd.com/read/29221500/analysis-of-naturally-occurring-resistance-associated-variants-to-ns3-4a-protein-inhibitors-ns5a-protein-inhibitors-and-ns5b-polymerase-inhibitors-in-patients-with-chronic-hepatitis-c
#14
Danhui Sun, Mingjia Dai, Shanshan Shen, Chunyang Li, Xuebing Yan
The first NS3/4A hepatitis C virus (HCV) protease inhibitors telaprevir and boceprevir were approved in 2011,and both NS5A and NS5B polymerase inhibitors were launched. Recently, direct-acting antivirals (DAAs) have had a major impact on patients infected with Hepatitis C virus (HCV). HCV DAAs are highly effective antivirals with fewer side effects. DAAs have been developed for treatment of HCV infection in combination with PEG-IFNα/RBV as well as in IFN-free regimens. However, some drug resistance mutations occur when a single oral DAA is used for treatment, which indicates that there is a low-frequency drug resistance mutation in HCV patients before the application of antiviral drugsOur research showed that natural resistance to HCV DAAs was found in treatment-naïve CHC patients and that the drug resistance mutation rates differ in various HCV genotypes...
December 8, 2017: Gene Expression
https://www.readbyqxmd.com/read/29217468/availability-of-hepatitis-c-diagnostics-and-therapeutics-in-european-and-eurasia-countries
#15
Hakan Leblebicioglu, Joop E Arends, Resat Ozaras, Giampaolo Corti, Lurdes Santos, Christoph Boesecke, Andrew Ustianowski, Ann-Sofi Duberg, Simona Ruta, Nermin N Salkic, Petr Husa, Ivana Lazarevic, Juan A Pineda, Natalia Yurievna Pshenichnaya, Tengiz Tsertswadze, Mojca Matičič, Edmond Puca, Gulzhan Abuova, Judit Gervain, Ramin Bayramli, Salih Ahmeti, Mairi Koulentaki, Badreddine Kilani, Adriana Vince, Francesco Negro, Mustafa Sunbul, Dominique Salmon
BACKGROUND: Treatment with direct acting antiviral agents (DAAs) has provided sustained virological response rates in >95% of patients with chronic hepatitis C virus (HCV) infection. However treatment is costly and market access, reimbursement and governmental restrictions differ among countries. We aimed to analyze these differences among European and Eurasian countries. METHODS: A survey including 20-item questionnaire was sent to experts in viral hepatitis...
December 4, 2017: Antiviral Research
https://www.readbyqxmd.com/read/29217381/adiponectin-levels-and-insulin-resistance-among-patients-with-chronic-hepatitis-c
#16
Raoni Freitas Carvalho, Ajax Mercês Atta, Isabela Silva de Oliveira, Taciana Pereira Sant'Ana Santos, João Pedro A Santos, Maria Isabel Schinoni, Maria Luiza Brito de Sousa-Atta
Chronic hepatitis C virus (HCV) infection is associated with insulin resistance (IR), rapid disease progression, and decreased virological response to antiviral treatment. In addition, obesity is a risk factor for chronic hepatitis C evolution and is associated with IR. As adiponectin is an adipokine that is associated with obesity and IR, this study aimed to investigate serum levels of adiponectin among patients with HCV infection and IR. Thirty-three patients with untreated HCV infection underwent testing of serum adiponectin levels (capture ELISA) and were compared to 30 healthy subjects with similar body mass indexes (BMI)...
December 4, 2017: Acta Tropica
https://www.readbyqxmd.com/read/29216721/alpha-2-macroglobulin-and-hyaluronic-acid-as-fibromarkers-in-patients-with-chronic-hepatitis-c
#17
B Pitekova, V Kupcova, E Uhlikova, V Mojto, L Turecky
BACKGROUND: Liver fibrosis is the final common pathway of chronic liver diseases of various etiology. From the practical standpoint, it would be ideal to have a noninvasive fibromarker. The aim of our study was to investigate the levels of alpha-2-macroglobulin, potential fibromarker, in correlation to histological staging and another potential fibromarker, hyaluronic acid, in patients with chronic hepatitis C. METHODS: Population groups in this study consisted of 51 healthy volunteers and 54 patients with chronic hepatitis C...
2017: Bratislavské Lekárske Listy
https://www.readbyqxmd.com/read/29216392/dioxin-like-pcb-126-increases-systemic-inflammation-and-accelerates-atherosclerosis-in-lean-ldl-receptor-deficient-mice
#18
Michael C Petriello, J Anthony Brandon, Jessie Hoffman, Chunyan Wang, Himi Tripathi, Ahmed Abdel-Latif, Xiang Ye, Xiangan Li, Liping Yang, Eun Lee, Sony Soman, Jazmyne Barney, Banrida Wahlang, Bernhard Hennig, Andrew J Morris
Exposure to dioxins and related persistent organic pollutants likely contributes to cardiovascular disease (CVD) risk through multiple mechanisms including the induction of chronic inflammation. Epidemiological studies have shown that leaner individuals may be more susceptible to the detrimental effects of lipophilic toxicants because they lack large adipose tissue depots that can accumulate and sequester these pollutants. This phenomenon complicates efforts to study mechanisms of pollutant-accelerated atherosclerosis in experimental animal models where high-fat feeding and adipose expansion limit the bioavailability of lipophilic pollutants...
December 1, 2017: Toxicological Sciences: An Official Journal of the Society of Toxicology
https://www.readbyqxmd.com/read/29216251/molecular-characterization-of-hepatitis-b-virus-in-bangladesh-reveals-a-highly-recombinant-population
#19
Saif Ullah Munshi, Thanh Thi Thanh Tran, Truc Nhu Thanh Vo, Shahina Tabassum, Nahida Sultana, Trang Hoa Nguyen, Munira Jahan, Chau Ngoc Le, Stephen Baker, Motiur Rahman
The natural history and treatment outcome of hepatitis B viruses (HBV) infection is largely dependent on genotype, subgenotype, and the presence or absence of virulence associated mutations. We have studied the prevalence of genotype and subgenotype as well as virulence and drug resistance associated mutations and prevalence of recombinant among HBV from Bangladesh. A prospective cross-sectional study was conducted among treatment naïve chronic HBV patients attending at Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh for HBV viral load assessment between June and August 2015...
2017: PloS One
https://www.readbyqxmd.com/read/29214477/prevalence-of-occult-hepatitis-c-virus-among-hemodialysis-patients-in-tanta-university-hospitals-a-single-center-study
#20
Ghada Abdelmoemen, Samy Abdelkader Khodeir, Sabry Abou-Saif, Abdelrahman Kobtan, Sherief Abd-Elsalam
Occult hepatitis C virus infection (OCI) is a newly defined type of infection by the chronic hepatitis virus (HCV) distinguished by the existence of HCV RNA in liver tissue and/or peripheral blood mononuclear cells (PBMCs) in patients whose plasma are devoid of both positive serology and RNA. Patients on maintenance hemodialysis evince a higher HCV prevalence than the general population due to high nosocomial transmission by the dialysis units. We investigated the prevalence of occult HCV infection in patients attending our university hemodialysis centers for maintenance hemodialysis...
December 6, 2017: Environmental Science and Pollution Research International
keyword
keyword
15261
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"